tbuckley/cabot-search huggingface dataset:
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report
Authors: Hong Li, Weijie Ma, Ken Y. Yoneda, Elizabeth H. Moore, Yanhong Zhang, Lee L. Q. Pu, Garrett M. Frampton, Michael Molmen, Philip J. Stephens, Tianhong Li
Journal: Journal of Hematology & Oncology (2017)

Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become standard of care for patients with advanced non-small cell lung cancer and increasing numbers of other cancer types. In this report, we discuss the clinical history, pathological evaluation, and genomic findings in a patient with metastatic lung squamous cell cancer (SCC) who developed severe nivolumab-induced pneumonitis preceding durable clinical remission after three doses of nivolumab. A patient with chemotherapy-refractory, metastatic lung SCC developed symptomatic pneumonitis by week 4 after nivolumab treatment, concurrently with onset of a potent antitumor response. Despite discontinuation of nivolumab after three doses and the use of high dose oral corticosteroids for grade 3 pneumonitis, continued tumor response to a complete remission by 3 months was evident by radiographic assessment. At the time of this submission, the patient has remained in clinical remission for 14 months. High PD-L1 expression by immunohistochemistry staining was seen in intra-alveolar macrophages and viable tumor cells in the pneumonitis and recurrent tumor specimens, respectively. Tumor genomic profiling by FoundationOne targeted exome sequencing revealed a very high tumor mutation burden (TMB) corresponding to 95–96 percentile in lung SCC, i.e., 87.4–91.0 and 82.9 mut/Mb, respectively, in pre- and post-nivolumab tumor specimens. Except for one, the 13 functional genomic alterations remained the same in the diagnostic, recurrent, and post-treatment, relapsed tumor specimens, suggesting that nivolumab reset the patient's immune system against one or more preexisting tumor-associated antigens (TAAs). One potential TAA candidate is telomerase reverse transcriptase (TERT) in which an oncogenic promoter -146C>T mutation was detected. Human leukocyte antigen (HLA) typing revealed HLA-A*0201 homozygosity, which is the prevalent HLA class I allele that has been used to develop universal cancer vaccine targeting TERT-derived peptides. Nivolumab could quickly reset and sustain host immunity against preexisting TAA(s) in this chemotherapy-refractory lung SCC patient. Further mechanistic studies are needed to characterize the effective immune cells and define the HLA-restricted TAA(s) and the specific T cell receptor clones responsible for the potent antitumor effect, with the aim of developing precision immunotherapy with improved effectiveness and safety.
Contents, Vol. 58, 1992
Authors: Philip Snaith, Myriam van Moffaert, Fabio Facchinetti, Giovanni A. Fava, Koen Demyttenaere, Loredana Fioroni, Isabella Neri, Andrea R. Genazzani, Erwin K. Koranyi, Walter M. Potoczny, Barry Blackwell, Rachel Rothschild, Frederic M. Quitkin, Jambur Ananth, Karen Johnson, Gustavo Rodrigo, Mabel Lusiardo, Randall S. Jorgensen, George E. Schreer, Lara Baskin, Monica Kolodziej, Patricia L. Dobkin, Robert O. Pihl
Journal: Psychotherapy and Psychosomatics (1992)
Association of the Timing of Pregnancy With Survival in Women With Breast Cancer
Authors: Javaid Iqbal, Eitan Amir, Paula A. Rochon, Vasily Giannakeas, Ping Sun, Steven A. Narod
Journal: JAMA Oncology (2017)

Increasing numbers of women experience pregnancy around the time of, or after, a diagnosis of breast cancer. Understanding the effect of pregnancy on survival in women with breast cancer will help in the counseling and treatment of these women.To compare the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period with that of women who had breast cancer but did not become pregnant.This population-based, retrospective cohort study linked health administrative databases in Ontario, Canada, comprising 7553 women aged 20 to 45 years at the time of diagnosis with invasive breast cancer, from January 1, 2003, to December 31, 2014.Any pregnancy in the period from 5 years before, until 5 years after, the index date of the diagnosis of breast cancer. Women were classified into the following 4 exposure groups: no pregnancy (the referent), pregnancy before breast cancer, pregnancy-associated breast cancer, and pregnancy following breast cancer.Five-year actuarial survival rates for all exposure groups, age-adjusted and multivariable hazard ratios [HRs] of pregnancy for overall survival for all exposure groups, and time-dependent hazard ratios for women with pregnancy following breast cancer.Among the 7553 women in the study (mean age at diagnosis, 39.1 years; median, 40 years; range, 20-44 years) the 5-year actuarial survival rate was 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy, 85.3% (95% CI, 82.8%-87.8%) for women with pregnancy before breast cancer (age-adjusted hazard ratio, 1.03; 95% CI, 0.85-1.27; P = .73), and 82.1% (95% CI, 78.3%-85.9%) for women with pregnancy-associated breast cancer (age-adjusted hazard ratio, 1.18; 95% CI, 0.91-1.53; P = .20). The 5-year actuarial survival rate was 96.7% (95% CI, 94.1%-99.3%) for women who had pregnancy 6 months or more after diagnosis of breast cancer, vs 87.5% (95% CI, 86.5%-88.4%) for women with no pregnancy) (age-adjusted HR, 0.22; 95% CI, 0.10-0.49; P < .001).Pregnancy did not adversely affect survival in women with breast cancer. For breast cancer survivors who wish to conceive, the risk of death is lowest if pregnancy occurs 6 months or more after diagnosis.
Generation of Multi-Specific CTL Lines Using Overlapping Pentadecapeptide Pools of Aspergillus f16 and Adenovirus Hexon Antigens Presented on Epstein Barr Virus-Transformed B Cells as Antigen Presenting Cells.
Authors: Fenlu Zhu, Barbara Davies, David A. Margolis, Carolyn A. Keever-Taylor
Journal: Blood (2006)
Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia
Authors: Irene M. Ghobrial, Jeffrey Matous, Swaminathan Padmanabhan, Ashraf Badros, Robert Schlossman, Stacey Chuma, Renee Leduc1, Marybeth Nelson, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, Steven P. Treon, Kenneth C. Anderson, Paul Richardson
Journal: Blood (2008)
Leiomyoma Originated From Inferior Vena Cava Mimicking an Adrenal Malignant Tumor on 18F-FDG PET/CT
Authors: Zhanli Fu, Meng Liu, Ziao Li, Jin Zhang, Qian Li
Journal: Clinical Nuclear Medicine (2017)

PET/CT was performed on an asymptomatic 62-year-old woman with a suspected adrenal mass and revealed the lesion with high 18F-FDG avidity and inferior vena cava involvement. A malignant nonfunctioning adrenal tumor was suspected. However, histopathology of the resected lesion revealed a leiomyoma arising from the inferior vena cava.
Eight Cycles of Escalated-Dose BEACOPP Compared With FourCycles of Escalated-Dose BEACOPP Followed by Four Cycles ofBaseline-Dose BEACOPP With or Without Radiotherapy in PatientsWith Advanced-Stage Hodgkin’s
Authors: Peter Borchmann, Heinz Haverkamp, Volker Diehl, Thomas Cerny, Jana Markova, Anthony Ho, Hans Theodor Eich, Hans Konrad Muller-Hermelink, Lothar Kanz, Richard Greil, Andreas Rank, Ursula Paulus, Lenka Šmardová, Christoph Huber, Bernd Dorken, Christoph Nerl, Stephan Krause, Rolf-Peter Mueler, Michael Fuchs, Andreas Engert
Journal: Journal of Clinical Oncology (2011)

PURPOSE: Eight cycles of BEACOPP(escalated) (escalated dose of
bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone) followed by
radiotherapy (RT) to initial bulk or residual tumor mass is the
German Hodgkin Study Group standard of care for advanced-stage
Hodgkin's lymphoma (HL). However, treatment-related toxicity is
a concern, and the role of RT in this setting is unclear. The
HD12 study thus aimed to reduce toxicity while maintaining
efficacy. PATIENTS AND METHODS: In this prospectively
randomized multicenter trial, eight cycles of
BEACOPP(escalated) was compared with four cycles of
BEACOPP(escalated) followed by four cycles of the baseline dose
of BEACOPP (BEACOPP(baseline); 4 + 4), and RT with no RT in the
case of initial bulk or residual disease. The study was
designed to exclude a difference in 5-year freedom from
treatment failure (FFTF) rate of 6%. RESULTS: Between January
1999 and January 2003, 1,670 patients age 16 to 65 years were
enrolled onto the HD12 study. At 5 years, FFTF was 86.4% in the
BEACOPP(escalated) arm and 84.8% in the 4 + 4 arm (difference,
-1.6%; 95% CI, -5.2% to 1.9%), and overall survival was 92%
versus 90.3% (difference, -1.7%; 95% CI, -4.6% to 1.1%). Deaths
related to acute toxicity of chemotherapy were observed in 2.9%
of patients (BEACOPP(escalated), n = 19; 4 + 4, n = 27). FFTF
was inferior without RT (90.4% v 87%; difference, -3.4%; 95%
CI, -6.6% to -0.1%), particularly in patients who had residual
disease after chemotherapy (difference, -5.8%; 95% CI, -10.7%
to -1.0%), but not in patients with bulk in complete response
after chemotherapy (difference, -1.1%; 95% CI, -6.2% to 4%).
CONCLUSION: The reduction of BEACOPP to the 4 + 4 regimen did
not substantially reduce severe toxicity but might decrease
efficacy. Our results do not support the omission of
consolidation RT for patients with residual disease.
Alternative strategies for improving the risk-to-benefit ratio
for patients with advanced HL are needed.
Clinical Safety of Long-Term Intravenous Itraconazole for the Treatment of Invasive Fungal Infection In Severely Ill Patients with Hematological Malignancies
Authors: Yaping Xie, Shenxian Qian, Daquan Gao, Xilian Huang, Pengfei Shi, Kuang Chen, Junfeng Tan, Lirong Liu
Journal: Blood (2010)
A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.
Authors: Fredrick O. Onono, Michael A. Morgan, H. Peter Spielmann, Douglas A Andres, Michaela Scherr, Letizia Venturini, Iris Dallman, Arnold Ganser, Christoph WM Reuter
Journal: Blood (2009)
MAP Kinase Activation Is Essential for the Development of Acute Leukemia by MLL Fusion Protein and FLT3 Tyrosine Kinase Mutation.
Authors: Ryoichi Ono, Hidetoshi Kumgai, Hideaki Nakajima, Yukio Tonozuka, Ai Hishiya, Tomohiko Taki, Yasuhide Hayashi, Toshio Kitamura, Tetsuya Nosaka
Journal: Blood (2006)
Structural Causes of Urban Firearm Violence
Authors: Jessica H. Beard, Carrie A. Sims
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Correlation of tumor size on preoperative breast MRI and pathologic tumor size in Asian patients
Authors: S. Lee, S. Kim, H. Kang, E. Lee, E. Kim, K. Ko, Y. Kwon
Journal: Journal of Clinical Oncology (2009)

e11546 Background: As many Asian patients want breast conserving therapy (BCT), use of magnetic resonance imaging (MRI) increase in preoperative diagnosis for breast cancer. But the impact of MRI on these patients has not been unclear. Methods: From January 2008 to July 2008, 423 patients underwent breast cancer surgery in National Cancer Center, Korea. We enrolled 357 patients consecutively in this retrospective study; 290 patients (non-MRI group) with preoperative mammography (MMG) and ultrasonography (US) vs. 66 patients (MRI group) with additional MRI to MMG, US and excluded 67 patients (42 patients with preoperative chemotherapy, 8 patients with ipsilateral recurrence, 17 patients whose MRI showed no residual lesion after excisional biopsy). We examined MRI effect on mastectomy rate, intraoperative conversion from BCT to mastectomy, positive margin rate in frozen specimen in both group. In MRI group, we evaluated the correlation between tumor size on US, MRI and pathologic tumor size. Results: Mean age of this study was 48.89 years (Non-MRI group: 50.70 years vs. MRI group: 46.33 years, p=0.001). The rate of mastectomy wasn’t different in both groups (Non-MRI group: 13.7% vs. MRI group: 19.4%, p=0.252). Intraoperative conversion to mastectomy was performed frequently in MRI group. (Non-MRI group: 1.7% vs. MRI group: 7.5%, p=0.023). But positive margin rate in frozen specimen was similar in both groups (Non-MRI group: 23.2% vs. MRI group: 34.0%, p=0.111). In MRI group, mean tumor size on MRI, US was 3.07cm, 1.98cm respectively. Mean pathologic tumor size was 2.67cm. The tumor size on MRI correlated strongly with the pathologic tumor size. The correlation coefficient was 0.732 (p=0.0001). But the tumor size on US didn’t correlate with the pathologic tumor size (p=0.066). In twenty nine patients whose MMG showed suspicious microcalcification, tumor size on MRI also correlated strongly with pathologic tumor size. The correlation coefficient was 0.693 (p=0.0001). But US didn’t show the correlation with the pathologic tumor size in these patients. Conclusions: Preoperative breast MRI didn’t give the impact on breast cancer surgery in Asian patients and could overestimate the size of tumor. But it could strongly correlate with the pathologic tumor size in Asian patients. No significant financial relationships to disclose.
Is erlotinib for first-line use in EGFR+ non-small-cell lung cancer cost-effective?
Authors: David L Veenstra, Preeti S. Bajaj, Josh John Carlson, Hans-Peter Goertz
Journal: Journal of Clinical Oncology (2013)

e19001 Background: A recent phase III clinical trial, EURTAC, demonstrated that first-line treatment with erlotinib significantly improved progression-free survival (PFS) compared with standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients whose tumors harbored epidermal growth factor receptor (EGFR) mutations (Rosell 2012). We sought to estimate the cost-utility of treatment with erlotinib in this patient population from the US payer perspective. Methods: We developed a Markov model with three health states: PFS, progression, and death. Patients received treatment until progression, unacceptable toxicity or death; patients randomized to chemotherapy received a maximum of 4 treatment cycles. Transition probabilities were extrapolated from the trial. Median PFS was 9.7 months in patients receiving erlotinib and 5.2 months in patients receiving chemotherapy (p&lt;0.0001). Cost and utility data were obtained from the literature. Probabilistic sensitivity analysis (PSA) was performed to assess uncertainty. We evaluated two scenarios: 1) first-line erlotinib vs. first-line chemotherapy, and 2) first-line erlotinib and mixed second-line treatments vs. first-line chemotherapy and second-line erlotinib. Results: First-line treatment with erlotinib vs. chemotherapy resulted in an increase of 0.60 life-years or 0.44 quality-adjusted life-years (QALYs). Mean total costs were $59,300 in the erlotinib arm and $17,800 in the chemotherapy arm, yielding an incremental cost-effectiveness ratio (ICER) of $98,338 with a 53% probability of being cost-effective at a willingness to pay (WTP) of $100,000/QALY. In the second scenario, the ICER was $50,002/QALY, with a 66% probability of being cost-effective. The main cost drivers in the model were the time spent in the PFS health state and drug costs. Conclusions: Treatment with erlotinib in first-line EGFR-positive NSCLC results in increased costs but also substantial increases in QALYs, demonstrating that this personalized approached to treatment may be cost-effective.
Erratum: High failure rate for an epicardial cardioverter-defibrillator lead; implications for long-term follow-up of patients with an implantable cardioverter-defibrillator (Journal of the American College of Cardiology (1998) 31 (616-22))
Authors: P. A. Brady, P. A. Friedman, J. M. Trusty, S. Grice, S. C. Hammill, M. S. Stanton
Journal: Journal of the American College of Cardiology (1998)
Abstract A63: Collective and individual migration after the epithelial-mesenchymal transition in engineered microenvironments
Authors: Ian Y. Wong
Journal: Cancer Research (2017)

Abstract Scattering and local dissemination of individual cells from a collective invasion front has been associated with the epithelial-mesenchymal transition (EMT). This phenotypic heterogeneity and plasticity has been challenging to reconstruct using classical assays which only measure population averages at endpoints. Here, we comprehensively track single cell invasion dynamics within engineered microenvironments such as microfabricated pillar arrays as well as 3D biomaterial scaffolds. After EMT induction through the master regulator Snail in mammary epithelial cells, we find distinct phenotypic subpopulations that display collective or individual migration behaviors. We show that these complex behaviors can be physically understood in terms of a phase transition during the solidification of binary alloys. Biologically, this conceptual framework addresses two essential mechanisms—phenotypic cell sorting and interconversion. We present new results to corroborate this model by systematically varying the composition of mosaic populations with both epithelial and EMT phenotypes. We also perturb these behaviors using migration-inhibiting compounds, revealing that different invasion phenotypes are correlated with differences in drug sensitivity. Altogether, this integration of engineered microenvironments with single cell resolution may permit new quantitative insights into the interplay of invasion, drug resistance and heterogeneity. Citation Format: Ian Y. Wong. Collective and individual migration after the epithelial-mesenchymal transition in engineered microenvironments. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A63.
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Authors: Francesco Costa, David van Klaveren, Stefan James, Dik Heg, Lorenz Räber, Fausto Feres, Thomas Pilgrim, Myeong-Ki Hong, Hyo-Soo Kim, Antonio Colombo, Philippe Gabriel Steg, Thomas Zanchin, Tullio Palmerini, Lars Wallentin, Deepak L Bhatt, Gregg W Stone, Stephan Windecker, Ewout W Steyerberg, Marco Valgimigli
Journal: The Lancet (2017)
Letter by Vallurupalli and Uretsky Regarding Article, “Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients With Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting)”
Authors: Srikanth Vallurupalli, Barry F. Uretsky
Journal: Circulation (2017)
A High Angiopoietin-2/Angiopoietin-1 Ratio Independently Predicts Septic Shock Development in Patients with Chemotherapy-Associated Febrile Neutropenia and Hematological Malignancies.
Authors: Maiara Marx Luz Fiusa, Carolina Costa-Lima, Gleice Regina Souza, Afonso Celso Vigorito, Francisco J P Aranha, Irene Lorand-Metze, Joyce M Annichino-Bizzacchi, Carmino Antonio De Souza, Erich V De Paula
Journal: Blood (2012)
Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.
Authors: Sonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, Teru Hideshima, Mariateresa Fulciniti, Samantha Pozzi, Loredana Santo, Diana Cirstea, Aliyah Rahemtullah, Eyal C. Attar, Alexander R Guimaraes, Dharminder Chauhan, Wanling Xie, Chirayu Patel, Jesse Schoonmaker, Michael Churchill, Kishan Patel, Edie Weller, Nikhil C. Munshi, Jasbir Seehra, Kenneth C. Anderson, David T. Scadden, Noopur Raje
Journal: Blood (2009)
ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer.
Authors: Nadia Harbeck, Daniel Hofmann, Oleg Gluz, Ronald E. Kates, Sherko Kümmel, Benno Nuding, Mahdi Rezai, Manfred Kusche, Claudia Schumacher, Ulrike Nitz
Journal: Journal of Clinical Oncology (2013)

TPS655^ Background: Indication of (neo-)adjuvant therapy is based on risk profile, hormone receptor and HER2 status at time of primary diagnosis. Data indicate dynamic proliferation changes after short-term induction therapy are superior to static initial biopsy results in predicting outcome and tumor response following neoadjuvant CTx in distinct BC subtypes. First generation trials such as TAILORx, MINDACT, NNBC-3, WSG planB utilize information of new prognostic/predictive tests to reduce overtreatment by CTx. Results still pending. ADAPT is a second generation trial addressing individualization of adjuvant decision-making in early BC by utilizing optimized pre-therapeutic biomarker information and early biomarker changes in a second core biopsy after 3-week subtype specific induction therapy. It aims at reducing over-/undertreatment in luminal tumors and optimizing therapy in HER2+ (T-DM1, pertuzumab) / TNBC (nab-paclitaxel + platinum/gemcitabine). Methods: Design: ADAPT combines static prognosis assessment by conventional markers (nodal status) and Recurrence Score (HR+) with dynamic measurement of proliferation changes after a short 3-week induction therapy, using the baseline diagnostic and repeat core biopsy following induction. ADAPT is a prospective, multi-center, controlled, non-blinded, randomized phase II/III trial, comprising an umbrella trial and 4 sub-trials (HR+/HER2-, HR+/HER2+, HR-/HER2+, TNBC). Eligibility criteria: Pre-/postmenopausal women with histologically confirmed unilateral primary invasive BC. Pts requiring CTx/targeted therapy with no contraindications. Statistics: Assumption across sub-protocols: CTx spared in 1120 HR+/HER2-, pCR achieved in 170 HER2+/TNBC pts. Outcome of good-proliferation responders/pCR pts will be compared to reference group (n=640 HR+/HER2- pts: low RS, no CTx, 94% 5yr survival). One-sided test of non-inferiority (3.2% margin, 90.8%) with alpha=0.05 will have 80% power. Present/target accrual:By 01/2013: 16/35 sites initiated. ADAPT HR+/HER2-: 161/4000 pts recruited. ADAPT HER2+/HR+: 9/380 pts recruited. ADAPT HER2+/HR- or TNBC: start of recruitment planned for Q2 2013. Clinical trial information: NCT01781338.
Identification of zfp148 (ZBP-89) as a Novel GATA-1 Associated Transcription Factor Involved in Megakaryopoiesis and Definitive Erythropoiesis.
Authors: Andrew J. Woo, Tyler B. Moran, Seong-Kyu Choe, Yocheved L. Schindler, Matthew R. Sullivan, Yuko Fujiwara, Barry H. Paw, Alan B. Cantor
Journal: Blood (2005)